Look for another strong year for medtech acquisitions in 2018 — and even potential bidding wars — predicts patent attorney David Dykeman.
The wave of mergers and acquisitions in the medical device industry should continue this year, both in terms of value and volume, according to patent attorney David Dykeman.
“Many large medtech companies are sitting on cash that they want to put to work to build out product pipelines,” said Dykeman, co-chair of international law firm Greenberg Traurig’s global Life Sciences & Medical Technology Group.
The firm is gearing up to host its fifth Medtech Partnering Day, on March 27 at its Boston office, gathering top innovators, investors and leaders from across New England’s medical technology industry. Dykeman said the international law firm hosts the event as a service to the medtech community to connect potential M&A candidates to large medical device acquirers.
The fevered M&A market of recent years could get an additional boost from the U.S. tax reforms passed at the end of last year, he added, noting that for medtech, acquisitions are still the most viable way to return value to stakeholders.